MARINO JAMES J

SEC source: 0001198578-26-000002 · form4-06292026_080625.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires 2036-06-25

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

SEC source: 0001415889-25-016217 · form4-06092025_080645.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Stock · 16,500 shares

Expires 2035-06-05

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

SEC source: 0001415889-24-027329 · form4-11202024_091142.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,204

F1 · shares: This transaction represents a gift transfer to an immediate family member of the reporting person who does not share the same household as the reporting person.

SEC source: 0001415889-24-017141 · form4-06172024_080622.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Stock · 16,500 shares

Expires 2034-06-13

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

SEC source: 0001415889-23-012227 · form4-08142023_090832.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,468

Underlying: Common Stock · 66,468 shares

Expires 2033-08-10

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001415889-23-010035 · form4-06202023_080610.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,300

Underlying: Common Stock · 11,300 shares

Expires 2033-06-15

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

SEC source: 0001415889-22-008913 · form4-08192022_010813.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,468

Underlying: Common Stock · 66,468 shares

Expires 2032-08-18

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001415889-22-006696 · form4-06172022_010659.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,600

Underlying: Common Stock · 13,600 shares

Expires 2032-06-16

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

SEC source: 0001179110-21-008955 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,334

SEC source: 0001179110-21-007789 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common stock · 13,000 shares

Expires 2031-07-30

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-21-006887 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2031-06-17

F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

SEC source: 0001179110-21-001782 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,716

SEC source: 0001179110-20-011442 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,716

SEC source: 0001179110-20-008195 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2030-07-09

F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-20-007588 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2030-06-18

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

SEC source: 0001179110-20-007165 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,704

SEC source: 0001179110-19-012058 · edgar.xml · derivative · entry 2

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2024-11-25

F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20.

SEC source: 0001179110-19-012058 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,942

F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20.

SEC source: 0001179110-19-010682 · edgar.xml · derivative · entry 5

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,472.5

Underlying: Series B Convertible Preferred Stock · 1,472.5 shares

Expires 2022-12-31

F6 · kind: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).

F6 · price: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).

SEC source: 0001179110-19-010682 · edgar.xml · derivative · entry 4

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Series B Convertible Preferred Stock · 1,472.5 shares

Expires not disclosed

F4 · derivative.exercise_price: These warrants were acquired in a public offering, by the Company, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425.

F6 · kind: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).

F6 · price: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).

F5 · derivative.expiration_date: The warrants were exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and would expire on the 18-month anniversary of the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.

SEC source: 0001179110-19-010682 · edgar.xml · derivative · entry 3

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Series A Convertible Preferred Stock · 5,000 shares

Expires 2022-12-31

F3 · kind: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).

F3 · price: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).

SEC source: 0001179110-19-010682 · edgar.xml · derivative · entry 2

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Series A Convertible Preferred Stock · 5,000 shares

Expires not disclosed

F1 · derivative.exercise_price: These warrants were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01.

F3 · kind: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).

F3 · price: In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).

F2 · derivative.expiration_date: The warrants were exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and would expire on the later of (i) the one-year anniversary of the date on which theCompany publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019.

SEC source: 0001179110-19-010682 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,942

SEC source: 0001179110-19-008868 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,833

Underlying: Common Stock · 5,833 shares

Expires 2029-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-19-007971 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires 2029-06-19

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

SEC source: 0001179110-18-010938 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,997

SEC source: 0001179110-18-010015 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2028-07-26

F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date.

SEC source: 0001179110-18-008561 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Common Stock · 67,000 shares

Expires 2028-06-13

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

SEC source: 0001179110-18-006013 · edgar.xml · derivative · entry 2

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,900

Underlying: Series B Convertible Prefered Stock · 1,472.5 shares

Expires not disclosed

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.

SEC source: 0001179110-18-006013 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,221

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).

SEC source: 0001179110-18-001967 · edgar.xml · derivative · entry 2

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Series A Convertible Preferred Stock · 5,000 shares

Expires not disclosed

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-222374).

F2 · derivative.expiration_date: The warrants are exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and will expire on the later of (i) the one-year anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019.

SEC source: 0001179110-18-001967 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,321

F1 · price: The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-222374).

SEC source: 0001179110-17-009168 · edgar.xml · derivative · entry 2

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-06-15

F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018.

SEC source: 0001179110-17-009168 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,997

F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions.

SEC source: 0001179110-17-008998 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Underlying: Common Stock · 1,500 shares

Expires 2027-06-12

F1 · derivative.exercise_date: These options vest over one year from the grant date in 12 equal monthly installments.

SEC source: 0001179110-17-006248 · edgar.xml · nonDerivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,321

SEC source: 0001179110-17-003487 · edgar.xml · derivative · entry 1

MARINO JAMES J · CIK 0001198578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2027-03-01

F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F2 · derivative.exercise_date: 100% of the total amount of shares subject to the Option vests on March 1, 2018.